azecort [bileni]
viatris healthcare limited - azelastino hidrochloridas/flutikazono propionatas - nosies purškalas (suspensija) - 137 µg/50 µg/dozėje - fluticasone, combinations
cinacalcet accord
accord healthcare b.v. - cinakalcetas - plėvele dengtos tabletės - 90 mg; 60 mg; 30 mg - cinacalcet
treclinac
viatris healthcare limited - klindamicinas/tretinoinas - gelis - 10 mg/0,25 mg/g - clindamycin, combinations
thioctacid t
meda pharma gmbh & co. kg - tiokto rūgštis - injekcinis tirpalas - 600 mg/24 ml - tioctic acid
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 100 mg - gabapentin
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 300 mg - gabapentin
gabapentin strides
strides pharma (cyprus) limited - gabapentinas - kietosios kapsulės - 400 mg - gabapentin
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials sisteminio naudojimo, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
zinforo
pfizer ireland pharmaceuticals - ceftarolino fosamilis - community-acquired infections; skin diseases, infectious; pneumonia - antibacterials sisteminio naudojimo, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.